NSE: PPLPHARMA · 2 November 2026
- Piramal Pharma has risen 22.76% over 5 trading sessions; today's move is +0.42%.
- Piramal Pharma announced its financial results for the quarter and half year ended September 30, 2026, reporting a 28% year-on-year growth in consolidated revenue from operations at ₹2,617 crores. EBITDA for the quarter surged 72% year-on-year to ₹385 crores with a margin expansion of over 350 basis points to 14.7%. Backed by robust performance across CDMO, Complex Hospital Generics, and Consumer Healthcare, management upgraded its FY27 revenue growth outlook to 19%–20%.
- Trading volume was 0.87 times the 20-day average daily volume.
Piramal Pharma share price: 22.76% rise over 5 trading sessions
Piramal Pharma Ltd. (PPLPHARMA) moved higher by 0.42% on Monday, closing at ₹239.92 compared to its previous close of ₹238.91. The stock opened at ₹238.52 and moved within an intraday range of ₹234.36 to ₹243.20, hitting a fresh 52-week high during the trading session.
The broader market demonstrated strong buying interest, with the benchmark Nifty advancing 1.68% on November 2, 2026. Meanwhile, the sector benchmark Nifty Pharma edged down by 0.07%, reflecting a divergence where Piramal Pharma managed to eke out gains despite a flat-to-negative sectoral backdrop, building on its strong recent momentum that includes a 21.03% gain over the past 20 trading days and a 22.76% gain over the past 5 trading days.
While no new corporate announcement was released on November 2, 2026, the equity continues to reflect sentiment from its late-October financial results for Q2 and H1 FY27, where consolidated revenue grew 28% year-on-year to ₹2,617 crores and EBITDA jumped 72% to ₹385 crores alongside an upgraded full-year outlook. Additionally, an October 31 filing showed that HDFC Mutual Fund disclosed a change in shareholding under Regulation 29(2), providing underlying institutional engagement context.
90.08 lakh shares traded by 2 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 1.04 crore shares (0.87 times). The five-day average daily volume was 3.51 crore shares. Separately, the NSE report for 2 November 2026 showed 30.99 lakh shares delivered, representing 34.40% of that day’s traded volume. The same report recorded 82,968 trades.
The stock's modest 0.42% gain to a new 52-week high of ₹243.20 appears consistent with ongoing positive sentiment following its late-October Q2 earnings beat and upgraded FY27 guidance, supported by healthy cash volume and recent institutional disclosure filings.
Latest Company Developments
Piramal Pharma announced its financial results for the quarter and half year ended September 30, 2026, reporting a 28% year-on-year growth in consolidated revenue from operations at ₹2,617 crores. EBITDA for the quarter surged 72% year-on-year to ₹385 crores with a margin expansion of over 350 basis points to 14.7%. Backed by robust performance across CDMO, Complex Hospital Generics, and Consumer Healthcare, management upgraded its FY27 revenue growth outlook to 19%–20%.
Strong operating performance and upgraded guidance provide fundamental support for investor sentiment and valuation re-rating.
The stock exchange received statutory disclosures under Regulation 29(2) of SEBI SAST Regulations regarding shareholding changes by HDFC Mutual Fund. Such filings track significant institutional stake adjustments in the company.
Institutional transaction filings highlight evolving portfolio positioning by major domestic funds.
The company announced that its commercial sales and distribution support arrangement with Bayer Pharmaceuticals Private Limited is scheduled to naturally expire on December 31, 2026, and will not be renewed. Piramal Pharma stated that the agreement accounts for less than 5% of consolidated revenue and expects no material impact on its profitability or financial position due to its commission-based nature.
Provides clarity on upcoming contract changes while confirming minimal financial vulnerability.
a press release dated October 27, 2026, titled "Piramal Pharma Limited Announces Results for Q2 and H1 FY2".
The exchange sought clarification from the company regarding a recent media report. Such a request is a verification step and does not by itself confirm the reported issue.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 12.71% on 30 September 2026. This compares with 13.18% on 30 June 2026, a change of -0.47 percentage points.
The filing reported 27 MF/UTI holders.
What to Watch Next
- Execution of upgraded FY27 revenue growth guidance of 19% to 20%
- Progress on CDMO order inflows and integration of the Yapan Bio acquisition
- Order book execution and customer audit outcomes across global facilities
- Management execution of the Bayer distribution transition ahead of December 2026 expiry
Other Dated Coverage
- Piramal Pharma Share Price Today: Rises 20.22% in 3 Trading Sessions | 30 October 2026 — 30 October 2026
- Piramal Pharma Share Price Today: Rises 16.04% in 2 Trading Sessions | 29 October 2026 — 29 October 2026
- Piramal Pharma Share Price Today: Rises 18.36% in 2 Trading Sessions | 28 October 2026 — 28 October 2026
More Piramal Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Piramal Pharma company news?
Piramal Pharma announced its financial results for the quarter and half year ended September 30, 2026, reporting a 28% year-on-year growth in consolidated revenue from operations at ₹2,617 crores. EBITDA for the quarter surged 72% year-on-year to ₹385 crores with a margin expansion of over 350 basis points to 14.7%. Backed by robust performance across CDMO, Complex Hospital Generics, and Consumer Healthcare, management upgraded its FY27 revenue growth outlook to 19%–20%.
How strong was Piramal Pharma’s trading volume?
90.08 lakh shares traded, 0.87 times the 20-day average daily volume. The price and volume data are dated 2 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.